|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
655600950[A03501621]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1º´(2005.04.01)(ÇöÀç¾à°¡)
\929 ¿ø/1º´(2003.10.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»ö-¹ÌȲ»öÀÇ °áÁ¤¼º ºÐ¸»ÀÌ ÃæÁøµÈ ¹ÙÀ̾ËÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1,10,50,100 VIAL |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
[À¯È¿±ÕÁ¾]
: Ȳ»öÆ÷µµ±¸±Õ, Ç¥ÇÇÆ÷µµ±¸±Õ, ȳ󼺿¬¼â±¸±Õ, Æó·Å±¸±Õ, ´ëÀå±Õ, ÇÁ·ÎÅ׿콺 ¹Ì¶óºô¸®½º, ¿£Å׷ιÚÅͼÓ, ÀÎÇ÷翣ÀÚ±Õ, Ŭ·¹ºê½Ã¿¤¶ó¼Ó, Àå³»±¸±Õ, ÀÓ±Õ
[ÀûÀÀÁõ]
ÁÖÈ¿´É È¿°ú : ÀÎÈĵο°, ±â°üÁö¿°, ±â°üÁöÆó·Å, Æó·Å, ¿äµµ¿°, ¹æ±¤¿°, ½Å¿ì½Å¿°, ¸ð³¶¿°, Á¶À§¿°, Ç¥Àú, ³óÇÇÁõ, Á¾°¡Áø, ³ó¾ç, ȳó¼ºÇǺο°, ÁßÀÌ¿°
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Cephalexin]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:129503BIJ ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] ¼ºÀÎ: ¼¼ÆÈ·º½Å¸®Áö³×ÀÌÆ®·Î¼ 1ȸ 0.5g(¿ª°¡) 1ÀÏ 2ȸ ±ÙÀ° ¶Ç´Â Á¤¸ÆÁÖ»çÇÑ´Ù. ÁßÁõ ¶Ç´Â °¨¼ö¼ºÀÌ ºñ±³Àû ³·Àº °¨¿°Áõ¿¡´Â 1ȸ 1g(¿ª°¡) 1ÀÏ 2ȸ ±ÙÀ° ¶Ç´Â Á¤¸ÆÁÖ»çÇÑ´Ù.
¾î¸°ÀÌ: 1ÀÏ Ã¼Áß kg´ç 20~50mg(¿ª°¡)À» 2ȸ ºÐÇÒ ±ÙÀ° ¶Ç´Â Á¤¸ÆÁÖ»çÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
ÀÌ ¾à¿¡ ÀÇÇØ ¼ïÀÇ º´·ÂÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
- ´ÙÀ½ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀ» ¿øÄ¢À¸·Î ÇÏÁö¸¸, ºÎµæÀÌÇÑ °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í :
º»Á¦ÀÇ ¼ººÐ ¶Ç´Â ¼¼Æè°è Ç×»ý¹°Áú¿¡ ´ëÇÏ¿© °ú¹ÎÁõÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ
Æä´Ï½Ç¸°°è Ç×»ý¹°Áú¿¡ ´ëÇØ °ú¹ÎÁõÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ
º»ÀÎ ¶Ç´Â ¾çÄ£, ÇüÁ¦ Áß¿¡ ±â°üÁöõ½Ä, ¹ßÁø, µÎµå·¯±â µîÀÇ ¾Ë·¹¸£±â Áõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀ» °¡Áø ȯÀÚ
½ÉÇÑ ½ÅÀå¾Ö ȯÀÚ
°æ±¸¼·Ãë°¡ ºÒ·®ÇÑ È¯ÀÚ ¶Ç´Â ºñ°æ±¸¿µ¾ç¿ä¹ý ȯÀÚ, Àü½Å»óŰ¡ ³ª»Û ȯÀÚ(ºñŸ¹ÎK °áÇÌÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ ÇàÇÒ °Í)
°í·ÉÀÚ |
| ÀÌ»ó¹ÝÀÀ |
- ¼ï:
µå¹°°Ô ¼ïÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ°í ºÒÄè°¨, ±¸³»ÀÌ»ó°¨, õ¸í, Çö±â, º¯ÀÇ, À̸í, ¹ßÇÑ µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
ÇǺÎ: µå¹°°Ô ¸®¿¤ÁõÈıº(Áßµ¶¼º Ç¥ÇDZ«»çÁõ), ÇǺÎÁ¡¸·¾ÈÁõÈıº(Stevens-JohnsonÁßÈıº)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
°ú¹ÎÁõ: ¾Æ³ªÇʶô½Ã, ¹ßÁø, µÎµå·¯±â, È«¹Ý, °¡·Á¿òÁõ, ¹ß¿, ¸²ÇÁÀý Á¾Ã¢, °üÀýÅë µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
Ç÷¾×: µå¹°°Ô °ú¸³±¸°¨¼Ò, È£»ê±¸Áõ°¡, È£»ê±¸°¨¼Ò, ¿ëÇ÷¼ººóÇ÷, ºóÇ÷, Ç÷¼ÒÆÇ°¨¼Ò°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°£Àå: µå¹°°Ô Ȳ´ÞÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶ÇÇÑ µå¹°°Ô GOT, GPT, AL-PÀÇ »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
½ÅÀå: µå¹°°Ô ±Þ¼º½ÅºÎÀü, °£Áú¼º½Å¿° µîÀÇ ½ÉÇÑ ½ÅÀå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î Á¤±âÀûÀ¸·Î °Ë»ç¸¦ ½Ç½ÃÇÏ´Â µî ÃæºÐÈ÷ °üÂûÇϰí ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
¼Òȱâ: µå¹°°Ô À§¸·¼º´ëÀå¿°µîÀÇ Ç÷º¯À» ¼ö¹ÝÇÏ´Â ½ÉÇÑ ´ëÀå¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. º¹Åë, ºó¹øÇÑ ¼³»ç°¡ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Áï½Ã Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. ¶ÇÇÑ ¶§¶§·Î ±¸¿ª, ±¸Åä, ¼³»ç, ¿¬º¯, º¹Åë, ½Ä¿åºÎÁø, À§ºÎºÒÄè°¨ µîÀÌ ³ªÅ¸³¯ ¼öÀÖ´Ù.
È£Èí±â: µå¹°°Ô ¹ß¿, ±âħ, È£Èí°ï¶õ, ÈäºÎ X¼± ÀÌ»ó, È£»ê±¸Áõ°¡ µîÀ» ¼ö¹ÝÇÏ´Â °£Áú¼º Æó·Å, PIEÁõÈıº µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ°í ºÎ½ÅÇÇÁúÈ£¸£¸óÁ¦ Åõ¿©µî ÀûÀýÇÑ Ã³Ä¡¸¦ÇÑ´Ù.
±Õ±³´ëÁõ: µå¹°°Ô ±¸³»¿°, ĵð´ÙÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ºñŸ¹Î°áÇÌÁõ: µå¹°°Ô ºñŸ¹Î K°áÇÌÁõ»ó(ÀúÇÁ·ÎÆ®·ÒºóÇ÷Áõ, ÃâÇ÷°æÇâµî), ºñŸ¹Î B±º °áÇÌÁõ»ó(¼³¿°, ±¸³»¿°, ½Ä¿åºÎÁø, ½Å°æ¿°µîÀÌ)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°ú·®Åõ¿©: °ú·®Åõ¿©½Ã º¹°Åõ¼® ¶Ç´Â Ç÷¾×Åõ¼®À¸·Î ¼¼ÆÈ·º½ÅÀÇ Ç÷û³óµµ¸¦ Å©°Ô °¨¼Ò ÇÒ ¼ö ÀÖ´Ù.
±âŸ: µå¹°°Ô µÎÅë, Çö±â, Àü½Å±Çۨ, Ç÷°üºÎÁ¾ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Cephalexin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Cephalexin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Cephalexin, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cephalexin interferes with an autolysin inhibitor.
|
| Pharmacology |
Cephalexin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations. It is effective against most gram-positive bacteria.
|
| Protein Binding |
Cephalexin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 14%
|
| Half-life |
Cephalexin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1 hour
|
| Absorption |
Cephalexin¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed from the gastrointestinal tract
|
| Pharmacokinetics |
Cephalexin lysinateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : ¾î¸° ¼Ò¾Æ¿¡¼´Â Áö¿¬µÈ´Ù. ½Å»ý¾Æ¿¡¼ 50%±îÁö Èí¼ö°¡ °¨¼ÒÇÒ ¼ö ÀÖ´Ù.
- ºÐÆ÷ :
- ´ã³¶, °£, ½ÅÀå, »À, Ÿ¾×, ´ãÁó, ´Á¸·¾×, Ȱ¾×À» Æ÷ÇÔÇÏ¿© ´ëºÎºÐÀÇ Ã¼³» Á¶Á÷°ú ü¾×¿¡ ³Î¸® ºÐÆ÷ÇÑ´Ù.
- ³úô¼ö¾×À¸·ÎÀÇ ºÐÆ÷´Â ¹Ì¹ÌÇÏ´Ù.
- ÅÂ¹Ý Åë°ú, À¯Áó ºÐÆ÷
- ´Ü¹é°áÇÕ : 6-15%
- ¹Ý°¨±â :
- ½Å»ý¾Æ : 5½Ã°£
- 3-12°³¿ùÀÇ ¼Ò¾Æ : 2.5 ½Ã°£
- ¼ºÀÎ : 0.5-1.2 ½Ã°£ (½ÅÀå¾Ö½Ã ¿¬Àå)
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æ±¸ : 1½Ã°£ À̳»
- ¼Ò½Ç : 8½Ã°£ À̳»¿¡ 80-100%°¡ ¹Ìº¯Èü·Î ½Å¹è¼³
|
| Biotransformation |
Cephalexin¿¡ ´ëÇÑ Biotransformation Á¤º¸ No appreciable biotransformation in the liver (90% of the drug is excreted unchanged in the urine).
|
| Toxicity |
Cephalexin¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting. The oral median lethal dose of cephalexin in rats is >5000 mg/kg.
|
| Drug Interactions |
Cephalexin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Probenecid Probenecid increases the antibiotic's level
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Cephalexin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take on empty stomach: 1 hour before or 2 hours after meals.
|
| Drug Target |
[Drug Target]
|
| Description |
Cephalexin¿¡ ´ëÇÑ Description Á¤º¸ A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of cephaloridine or cephalothin, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. [PubChem]
|
| Dosage Form |
Cephalexin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralPowder, for solution OralPowder, for suspension OralSuspension OralTablet Oral
|
| Drug Category |
Cephalexin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial AgentsCephalosporins
|
| Smiles String Canonical |
Cephalexin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=C(N2C(SC1)C(NC(=O)C(N)C1=CC=CC=C1)C2=O)C(O)=O
|
| Smiles String Isomeric |
Cephalexin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CC=CC=C1)C2=O)C(O)=O
|
| InChI Identifier |
Cephalexin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1/f/h18,22H
|
| Chemical IUPAC Name |
Cephalexin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2016-11-21
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. CEPHALEXIN[GGT Increase][Composite Activity](Score) NA(Marginal) 0(Active) 0[Alkaline Phosphatase Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[SGOT Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[SGPT Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[LDH Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA[GGT Increase](Activity Score) NA(Number of Rpts) NA(Index value) NA
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|